These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 12870435)
1. Drug resistance mechanisms in cancer cells: a proteomics perspective. Verrills NM; Kavallaris M Curr Opin Mol Ther; 2003 Jun; 5(3):258-65. PubMed ID: 12870435 [TBL] [Abstract][Full Text] [Related]
2. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents. O'Connor R; Clynes M; Dowling P; O'Donovan N; O'Driscoll L Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):805-17. PubMed ID: 18028026 [TBL] [Abstract][Full Text] [Related]
3. Casting light on molecular events underlying anti-cancer drug treatment: what can be seen from the proteomics point of view? Kraljevic S; Sedic M; Scott M; Gehrig P; Schlapbach R; Pavelic K Cancer Treat Rev; 2006 Dec; 32(8):619-29. PubMed ID: 17069979 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer. Uzzo RG; Haas NB; Crispen PL; Kolenko VM Cancer; 2008 Apr; 112(8):1660-71. PubMed ID: 18278811 [TBL] [Abstract][Full Text] [Related]
8. Prediction of broad spectrum resistance of tumors towards anticancer drugs. Efferth T; Konkimalla VB; Wang YF; Sauerbrey A; Meinhardt S; Zintl F; Mattern J; Volm M Clin Cancer Res; 2008 Apr; 14(8):2405-12. PubMed ID: 18413831 [TBL] [Abstract][Full Text] [Related]
9. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Hazlehurst LA; Landowski TH; Dalton WS Oncogene; 2003 Oct; 22(47):7396-402. PubMed ID: 14576847 [TBL] [Abstract][Full Text] [Related]
10. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
11. Integrins and extracellular matrix: a novel mechanism of multidrug resistance. Elliott T; Sethi T Expert Rev Anticancer Ther; 2002 Aug; 2(4):449-59. PubMed ID: 12647988 [TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance in cancer therapy: role of the microenvironment. Galmarini CM; Galmarini FC Curr Opin Investig Drugs; 2003 Dec; 4(12):1416-21. PubMed ID: 14763126 [TBL] [Abstract][Full Text] [Related]
13. Resistance mechanisms in human lung cancer. Mattern J; Volm M Invasion Metastasis; 1995; 15(3-4):81-94. PubMed ID: 8621273 [TBL] [Abstract][Full Text] [Related]
14. Use of proteomics to study chemosensitivity. Poland J; Wandschneider S; Urbani A; Bernardini S; Federici G; Sinha P Methods Mol Med; 2005; 111():267-81. PubMed ID: 15911985 [TBL] [Abstract][Full Text] [Related]
15. Bypassing cancer drug resistance by activating multiple death pathways--a proposal from the study of circumventing cancer drug resistance by induction of necroptosis. Hu X; Xuan Y Cancer Lett; 2008 Feb; 259(2):127-37. PubMed ID: 18082322 [TBL] [Abstract][Full Text] [Related]
16. Cancer proteomics and its application to discovery of therapy response markers in human cancer. Smith L; Lind MJ; Welham KJ; Cawkwell L; Cancer; 2006 Jul; 107(2):232-41. PubMed ID: 16752413 [TBL] [Abstract][Full Text] [Related]
17. Overcoming drug resistance in patients with metastatic breast cancer. Wong ST; Goodin S Pharmacotherapy; 2009 Aug; 29(8):954-65. PubMed ID: 19637949 [TBL] [Abstract][Full Text] [Related]
19. [Research advance on role of tumor microenvironment in mediating acquired drug resistance]. Ma XL; Xing H; Ma D Ai Zheng; 2007 Aug; 26(8):923-6. PubMed ID: 17697561 [TBL] [Abstract][Full Text] [Related]
20. Current strategies in overcoming resistance of cancer cells to apoptosis melanoma as a model. Hersey P; Zhuang L; Zhang XD Int Rev Cytol; 2006; 251():131-58. PubMed ID: 16939779 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]